Saturday, September 23, 2023
Saturday, September 23, 2023

Fujifilm Systems Integration Selects caresyntax for OR Integration

Today FUJIFILM Medical Systems announced that the company has selected caresyntax, a pioneering developer in surgical automation, analytics software, as the supplier of Fujifilm Systems Integration using caresyntax’s proprietary operating room (OR) integration and workflow automation intelligence.

As the healthcare industry continues to respond to today’s uncertainties, Fujifilm trusts this new partnership to aid hospital operations, improve workflow efficiencies of the interventional space, and meet patient demand surges as deferred procedures are rescheduled.

“As the only vendor that offers endoscopic imaging as well as modality solutions and enterprise-wide IT products—launching the Fujifilm Systems Integration business will allow Fujifilm to capture the full clinical value chain,” says Devon Bream, MPH, FACHE, Global Vice President Endoscopy, General Manager Systems Integration, FUJIFILM Medical Systems U.S.A., Inc. “We selected caresyntax as our supplier because the team has a demonstrated history in developing data-driven integration that provides the total visibility to achieve increased workflow efficiency, patient safety, and surgical performance.”

Together Fujifilm and caresyntax will develop a systems integration solution designed specifically for image and data integration in the operating room (OR/Hybrid OR) and endoscopy suite that will connect Fujifilm’s medical image capture products and Synapse brand viewing, storage, and analytics technologies.

“Fujifilm’s vision of closing the loop between its powerful clinical informatics ecosystem and its trusted offerings at the point of care will be a resounding success that will create value for caregivers and patients,” says Dennis Kogan, Co-Founder and CEO, caresyntax. “caresyntax is excited to leverage our robust surgical automation and analytics platform to support Fujifilm in this endeavor. We strongly believe that data-driven collaborations with health systems, medical device companies, and insurers are key to managing surgical risk and promoting smarter, safer surgery; and are proud to partner with Fujifilm in pursuit of this common goal.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase...

The EV-302 study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), compared to chemotherapy. An Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy boundary at interim analysis. The safety results of the combination are consistent with those of enfortumab vedotin in combination with pembrolizumab previously reported in cisplatin-ineligible patients with la/mUC.

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

"Dosing the first patient, on time, is a testament to our commitment to the clinical development of DA-1241 in patients with NASH," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "Based on the pre-clinical and clinical evidence generated to date, DA-1241 has demonstrated reduced hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control, and was shown to be well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM). Given this data, we believe that the mechanism of action of this promising cardiometabolic asset will translate into a safe and effective treatment for NASH, a disease with no current treatment options. The two-part design of this trial provides optionality for a potential interim analysis in the first half of 2024 and we expect to report the full data in the second half of 2024."

Medmain Inc. Has Been Selected for the U.S. Market Gateway Accelerator for BioSciences and MedTech

The "U.S. Market Gateway Accelerator for BioSciences and MedTech", sponsored by WorldUpstart, LLC, is an acceleration program that provides medical tech and life sciences startups with a proven track record outside the U.S. with the opportunity to enter and grow their business in the U.S. market.

Karger Publishers New Journal – Immune System

“Immune System is an innovative Open Access journal, welcoming articles with a broad background from basic science to clinical research, as long as the manuscript focuses on certain aspects of our immune response,” states editor-in-chief Désirée Larenas-Linnemann."

MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

Robert Barrow, Chief Executive Officer and Director of MindMed. “Thanks in large part to the enthusiasm we have seen regarding MM-120 among investigators and patients, as well as the strong execution of our team, we were able to enroll almost 200 participants in this trial in just over a year. We anticipate sharing topline results during the fourth quarter of this year.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy